Author

Tamara Lukić

Observed name: Tamara Lukic

Observed institutions: GlaxoSmithKline (United Kingdom), Queen Mary Hospital, Erasmus MC, University of Saskatchewan, Nanfang Hospital, National University Health System, Southern Medical University, University of Hong Kong

ORCID: 0000-0001-5963-0750

Observed ORCID: 0000-0001-5963-0750

OpenAlex ID: A5047971884

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

2022 · Man-Fung Yuen, Seng-Gee Lim, et al. · New England Journal of Medicine · 317

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection

2026 · Jinlin Hou, Seng-Gee Lim, et al. · New England Journal of Medicine · 47

Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

2022 · Man-Fung Yuen, Robert Plesniak, et al. · Journal of Hepatology · 8

A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)

2024 · Nadia Noormohamed, Tamara Lukic, et al. · Clinical Pharmacology in Drug Development · 4

Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

2022 · Seng Gee Lim, Cristina Pojoga, et al. · Journal of Hepatology · 4

TOP-598 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: results from the B-Sure study

2026 · Seng Gee Lim, Tarik Asselah, et al. · Journal of Hepatology · 2

WED-587 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: results from the B-Sure study

2026 · Seng Gee Lim, Manuela Arbune, et al. · Journal of Hepatology · 2

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

2022 · Bassam Mahboub, Ahmed Mohy, et al. · ClinicoEconomics and Outcomes Research · 2

P197 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-clear not-on-NA responders: results from the B-sure study

2026 · Stuart Flanagan, Seng Gee Lim, et al. · Gut

P194 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-clear on-nucleos(t)ide analogue responders: results from the B-sure study

2026 · Seng Gee Lim, Tarik Asselah, et al. · Gut

O8 Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-well phase 3 trials

2026 · Jinlin Hou, Seng Gee Lim, et al. · Gut

WED-577 Up to 24 months durability of functional cure in response to bepirovirsen plus Peg-IFN sequential therapy in B-Together responders: results from the B-Sure study

2026 · Carla Coffin, Pietro Andreone, et al. · Journal of Hepatology

GS-001 Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well phase 3 trials

2026 · Jinlin Hou, Seng Gee Lim, et al. · Journal of Hepatology

Works count: 13

Citation count: 386

H-index: 4

I10-index: 2